Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Improving Access to Genetic Testing and Counseling
Dr. Angela Bradbury is leading a study on access to genetic testing and genetic counseling, including a telehealth option.
A Year in Review: 2020
Although COVID-19 dominated the news, important new research and clinical trials began for pancreatic cancer patients.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Using Tumor Tissue Samples to Break Down Assumptions About Pancreatic Cancer
Dr. Christine Iacobuzio-Donahue uses tumor tissue samples to study how pancreatic cancer tumors develop, so she can find ways to stop the disease.
Studying One Family’s Mutations May Change Pancreatic Cancer Treatment and Prevention
Dr. Sahar Nissim is studying the genetic mutations in one family predisposed to pancreatic cancer, to find new ways to combat the disease.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.